Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 5/20 | 0.34 |
| ▸ | HTR2C | P28335 | 5/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125610 | 0.84 | SMN1; SMN2 (0.39) | CYP1A1CYP1B1HTR2AHTR2CMTNR1A | |
| Hydrochloric Acid SCHEMBL126500 | 0.81 | MTNR1A (0.37) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL126045 | 0.73 | MTNR1A (0.60) | MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL8812164 | 0.70 | MAPK1 (0.42) | — | |
| SCHEMBL126115 | 0.70 | MEN1 (0.49) | CYP1A1CYP1B1MTNR1AMTNR1BMEN1 | |
| SCHEMBL125392 | 0.69 | HTR2A (0.40) | HTR2AHTR2C | |
| SCHEMBL11258179 | 0.65 | CA1 (0.43) | HTR2AHTR2CMEN1KMT2A | |
| SCHEMBL11732827 | 0.64 | KDM4E (0.40) | MEN1KMT2A | |
| SCHEMBL11733303 | 0.64 | KDM4E (0.40) | MEN1KMT2A | |
| SCHEMBL11732684 | 0.64 | NPC1 (0.50) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2100895-B1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-03-07 | — | — | EP | disclosed |
| EP-2100895-B1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2100895-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-16 | — | — | EP | disclosed |
| EP-2100895-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | MTNR1A, MTNR1B, AHR | CYP1A1 96/4885CYP1B1 239/4885HTR2A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.